- Home
- ARQT vs CXW Comparison
ARQT vs CXW Comparison
Compare ARQT & CXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- CXW
- Stock Information
- Founded
- ARQT 2016
- CXW 1983
- Country
- ARQT United States
- CXW United States
- Employees
- ARQT N/A
- CXW N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- CXW Real Estate Investment Trusts
- Sector
- ARQT Health Care
- CXW Real Estate
- Exchange
- ARQT Nasdaq
- CXW Nasdaq
- Market Cap
- ARQT 2.1B
- CXW 2.4B
- IPO Year
- ARQT 2020
- CXW 1997
- Fundamental
- Price
- ARQT $20.86
- CXW $17.96
- Analyst Decision
- ARQT Strong Buy
- CXW Strong Buy
- Analyst Count
- ARQT 7
- CXW 3
- Target Price
- ARQT $19.00
- CXW $33.33
- AVG Volume (30 Days)
- ARQT 2.0M
- CXW 934.4K
- Earning Date
- ARQT 10-28-2025
- CXW 11-05-2025
- Dividend Yield
- ARQT N/A
- CXW N/A
- EPS Growth
- ARQT N/A
- CXW 57.89
- EPS
- ARQT N/A
- CXW 0.95
- Revenue
- ARQT $263,464,999.00
- CXW $1,997,643,000.00
- Revenue This Year
- ARQT $72.46
- CXW $9.19
- Revenue Next Year
- ARQT $31.69
- CXW $10.74
- P/E Ratio
- ARQT N/A
- CXW $18.93
- Revenue Growth
- ARQT 99.50
- CXW 1.62
- 52 Week Low
- ARQT $8.03
- CXW $12.66
- 52 Week High
- ARQT $21.84
- CXW $24.99
- Technical
- Relative Strength Index (RSI)
- ARQT 59.00
- CXW 32.20
- Support Level
- ARQT $20.34
- CXW $17.58
- Resistance Level
- ARQT $21.84
- CXW $18.37
- Average True Range (ATR)
- ARQT 1.09
- CXW 0.63
- MACD
- ARQT -0.00
- CXW -0.19
- Stochastic Oscillator
- ARQT 65.37
- CXW 8.30
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About CXW CoreCivic Inc.
CoreCivic Inc is an owner and operator of private prisons and detention centers in the United States. It operates in three segments: Safety, Community, and Properties. The Community segment owns and operates residential reentry centers. The Properties segment owns properties for lease to third parties and government agencies. The vast majority of the company's revenue comes from the CoreCivic Safety segment which consists of correctional and detention facilities that are owned, or controlled via a long-term lease, and managed by the company, as well as those correctional and detention facilities owned by third parties but managed by CoreCivic.